ARS Pharmaceuticals (SPRY) Return on Sales (2022 - 2026)

ARS Pharmaceuticals has disclosed Return on Sales across 5 years of filings, most recently posting 0.03% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.03%, up 2.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY), and the FY2025 annual result was 0.02%, down 2.0% from the prior year.
• Return on Sales came in at 0.03% for Q1 2026 at ARS Pharmaceuticals, down from 0.04% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.04% in Q4 2025 to a low of 24.25% in Q3 2023.
• The 5-year median for Return on Sales is 0.14% (2022), against an average of 3.84%.
• Across the five-year window, Return on Sales plunged 2389 bps in 2023 and jumped 2414 bps in 2024, its largest moves.
• ARS Pharmaceuticals' Return on Sales stood at 0.27% in 2022, then plunged by 1310 bps to 3.81% in 2023, then surged by 100 bps to 0.01% in 2024, then jumped by 566 bps to 0.04% in 2025, then plunged by 176 bps to 0.03% in 2026.
• The last three Return on Sales figures came in at 0.03% (Q1 2026), 0.04% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.